Skip Navigation



American Journal of Epidemiology Advance Access published online on June 12, 2008
American Journal of Epidemiology, doi:10.1093/aje/kwn141
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
168/3/250    most recent
kwn141v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Agalliu, I.
Right arrow Articles by Stanford, J. L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agalliu, I.
Right arrow Articles by Stanford, J. L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

American Journal of Epidemiology © The Author 2008. Published by the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org.

Original Contribution

Statin Use and Risk of Prostate Cancer: Results from a Population-based Epidemiologic Study

Ilir Agalliu1,2, Claudia A. Salinas1,3, Philip D. Hansten4, Elaine A. Ostrander5 and Janet L. Stanford1,3

1 Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
2 Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY
3 Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA
4 Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA
5 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Correspondence to Dr. Janet L. Stanford, Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, 1100 Fairview Avenue N, M4-B874, Seattle, WA 98109-1024 (e-mail: jstanfor{at}fhcrc.org).

Received for publication February 23, 2008. Accepted for publication May 1, 2008.

Epidemiologic studies of statin use in relation to prostate cancer risk have been inconclusive. Recent evidence, however, suggests that longer-term use may reduce risk of more advanced disease. The authors conducted a population-based study of 1,001 incident prostate cancer cases diagnosed in 2002–2005 and 942 age-matched controls from King County, Washington, to evaluate risk associated with statin use. Logistic regression was used to generate odds ratios for ever use, current use, and duration of use. No overall association was found between statin use and prostate cancer risk (odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2 for current use; OR = 1.1, 95% CI: 0.7, 1.8 for >10 years' use), even for cases with more advanced disease. Risk related to statin use, however, was modified by body mass index (interaction p = 0.04). Obese men (BMI ≥30 kg/m2) who used statins had an increased risk (OR = 1.5, 95% CI: 1.0, 2.2) relative to obese nonusers, with a stronger association for longer-term use (OR = 1.8, 95% CI: 1.1, 3.0 for ≥5 years' use). Although statin use was not associated with overall prostate cancer risk, the finding of an increased risk associated with statin use among obese men, particularly use for extended durations, warrants further investigation.

case-control studies; hydroxymethylglutaryl-CoA reductase inhibitors; obesity; odds ratio; prostatic neoplasms

Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; PSA, prostate-specific antigen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.